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http://www.biomedcentral.com/1471-2490/13/25RESEARCH ARTICLE Open AccessUrinary high molecular weight matrix
metalloproteinases as non-invasive biomarker for
detection of bladder cancer
Mohammed A Mohammed1, Manar F Seleim2, Mohga S Abdalla2, Hayat M Sharada2
and Abdel Hady A Abdel Wahab1*Abstract
Background: Matrix Metalloproteinases (MMPs) are key molecules for tumor growth, invasion and metastasis.
Over-expression of different MMPs in tumor tissues can disturb the homeostasis and increase the level of various
body fluids. Many MMPs including high molecular weights (HMWs) were detected in the urine of prostate and
bladder cancer patients. Our aim here is to assess the usefulness of HMW MMPs as non invasive biomarkers in
bilharzial bladder cancer in Egyptian patients.
Methods: The activity of different MMPs including HMW species was determined using zymographic analysis
technique in the urine samples procured from sixty six bladder cancer patients (bilharzial and non-bilharzial) as well
as hundred healthy control subjects. Also, the correlation between these HMW MMPs activities and different
clinico-pathological parameters was investigated.
Results: High frequency of urine MMPs (uMMPs) activity was determined in 63.6% of examined tumor cases,
however, none of the control cases showed any uMMPs activity. MMP-9 had the highest activity (62%) followed by
MMP9/NGAL (60%), MMP-2 (54.5%), MMP-9 dimer (53%), ADAMTS (25.6%), and the lowest one was MMP-9/TIMP-1
(12%) only. There was no correlation between uMMPs and any of clinico-pathological parameters including age,
gender, tumor size and type, bilharziasis, grade, lymph node involvement, and invasion to the prostate. A significant
correlation was established only between MMP-9/TIMP-1 activities with the tumor size.
Conclusions: This study revealed that the detection of urinary MMPs including HMWs activity might be sensitive
biomarkers for prediction of bladder cancer. It is also demonstrate that the detection of these urinary HMW
gelatinases could not differentiate between bilharzial and non bilharzial bladder cancer subtypes.
Keywords: Bladder cancer, High molecular weight matrix metalloproteinases, Early detection, BiomarkersBackground
Bladder cancer is the most common cancer in Egypt
during the past 50 year [1,2]. The most common histo-
pathological type of bladder cancer in Egypt is the squa-
mous cell carcinoma (SCC), constituting from 59% to
81% between 1960–1981 [3]. Chronic bladder infection
with schistosoma haematobium is the most important
risk factor for bladder cancer [4]. Oncologists and pa-
thologists have suggested that the ratio between SCC:* Correspondence: abdelhadya@gmail.com
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distribution, and reproduction in any mediumTCC (transitional cell carcinoma) types of bladder can-
cer was changed over the past 10–15 years. This is be-
cause the change in the etiology of bladder cancer [5].
Definitive diagnosis of bladder cancer requires invasive
cystoscopic examination. Despite urinary cytology is
widely used for screening for bladder cancer, it is some-
times difficult to judge cytological specimens [6]. There-
fore, non invasive and sensitive method is required for
screening, diagnosis or even for monitoring of the
disease.
The extracellular matrix (ECM) has a central role in
organizing tissue architecture in animals and humans,
providing the structural scaffold for cells. However,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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namic system that interacts with cells and influences
their functions such as cell proliferation, growth, differ-
entiation, migration, adhesion and survival. Conversely,
cells are also able to influence and reorganize their sur-
rounding ECM. ECM-cell interaction is essential to
maintaining the physiological microenvironment and
homeostasis. Any disturbance in this complex regulation
have been implicated in several pathological processes
including unregulated tumor growth, invasion and me-
tastasis [7]. Overexpression of MMPs in tumor tissues
and stroma can increase level of MMPs activities in vari-
ous body fluids. Multiple lines of evidence show that
MMPs can be detected in urine samples procured from
patients suffering prostate and bladder cancers and
MMPs were independent predictor of disease status
[8,9]. Several MMP species were detected in urine from
cancer patients including MMP-2, MMP-9, MMP-9/
NGAL. Several studies identified three high molecular
weight gelatinases in urine of bladder cancer patients
[10,11]. These MMPs were MMP-9 and its inhibitor
TIMP-1 (140KDa), MMP-9 dimer (220KDa), and disin-
tegrin and metalloproteinase with thrombospondin
motifs-7 (ADAMTs-7) [12].
The objective of the current study is to identify the
different gelatinases activity in the urine samples col-
lected from bilharzial bladder cancer patients (in par-
ticular HMW gelatinases) and to correlate their activities
with different clinico-pathological parameters of the
disease.Table 1 Clinical features of bladder cancer patients in the pre
Clinical parameters Bilharzial bladder cancer subgr
n = 22(%)
Gender Male 18 (27.3)
Female 4 (6.1)
Age (yrs) ≤ 60 7 (10.6)
>60 15 (22.7)
Tumor size ≤ 5 cm 4 (6.1)
>5 cm 18 (27.3)
Tumor type TCC 13 (19.7)
SCC 9 (13.6)
Tumor grade 1/2 16 (24.5)
3/4 5 (7.7)
Missing 1 (1.5)





Clinical features of bladder cancer patients
This study was conducted in a compliance with the
guidelines of good ethical principles rooted in the Dec-
laration of Helsinki. All patients consented to participate
in the study. The study was approved by the Institutional
Review Board of the Egyptian National Cancer Institute
NCI-Egypt This study encompassed 66 bladder cancer
patients presented to NCI-Egypt from April 2008 to
May 2011. Another 100 healthy control groups without
any history of cancer, inflammation, or immunodefi-
ciency diseases were also included with average age of
51 ± 6 years (75 males and 25 females). The average age
of bladder cancer group was 54 ± 8 years (48 males and
18 females). Transitions cell carcinoma type was about
68% of all patients, SCC was 32%. Grade II was the com-
mon histological grade of the tumor (56%) whereas GI
and GIII were about 9.1% and 30% respectively. Tumors
associated with bilharziasis were 33% and the free of bil-
harziasis were 67%. The percentage of positive lymph
nodes was 6%. About 44% of the tumors had muscle in-
filtrated and about 15% had metastatic to prostate
(Table 1).
Sample collection and processing
Fresh voided urine samples were obtained before sur-
gical or other therapeutic intervention. Samples were
collected in sterile containers and immediately frozen
at −20°C. Urine was tested for presence of blood or
leucocytes using urine analysis strips and the samplessent study
oup Non- bilharzial bladder cancer subgroup Total
n = 44 (%)
30 (45.5) 48 (72.7)
14 (21.1) 18 (27.3)
20 (30.3) 27 (40.9)
24 (36.4) 39 (59.1)
24 (36.4) 28 (42.4)
20 (30.2) 38 (57.6)
32 (48.5) 45 (68)
12 (18.2) 21 (32)
27 (40.4) 43 (65)
15 (22.9) 20 (30)
2 (3.0) 3 (5)
2 (3) 4 (6)
42 (63.6) 62 (94)
5(7.6) 10 (15.2)
39 (59) 56 (84.8)
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study. Protein concentration was measured in all urine
supernatant by the Bradford method according to the
manufacturer’s protocol (Bio-Rad, CA).
Zymographic analysis
Gelatinases in the urine were detected using gelatin
zymography as previously described [10]. Briefly, 40 μL
urine samples from controls or cancer patients were
mixed with non- reducing sample buffer (4% SDS,
0.15 M Tris, pH 6.8, 20% v/v glycerol, and 0.5% w/v
bromphenol blue) and separated on a 10% polyacryl-
amide gel containing 0.1% gelatin (Bio-Rad, Hercules,
CA). After electrophoresis, gels were washed twice with
2.5% Triton X-100 (15 min/each wash). Substrate diges-
tion was carried out by incubating the gel in 50 mM
Tris- HCl, pH 7.6, containing 5 mM CaCl2, 1 μM ZnCl2,
1% Triton X-100, and 0.02% NaN3 at 37°C for 24 h. The
gel was stained with 0.1% Coomassie Brilliant Blue R250
(Bio-Rad). Molecular weight protein marker appeared as
easily visible staining bands against the lighter blue color
of 108 the stained gel background. Gelatinase activity
was detected as zones of clearance on a background of
uniform blue staining and imaged using densitometer
(BIOMETRA).
Statistical analysis
The patients were described using descriptive statistics
functions. Nominal and categorical variables were sum-
marized as percentages while numerical data as means
and standard deviation. Sub-groups were compared
using Chi Squared test when dealing with nominal or
categorical variable and independent t-test or ANOVA
when comparing numerical values. Groups were com-
pared using the log-rank test. A Probability less thanFigure 1 Urine samples procured from bladder cancer patients were
enzyme activity were detected as zones of clearance on a background of u
weight. Arrows indicate HMW MMP9 dimer, MMP9-NGAL complex, MMP9.
for MMPs, while no activity in urine sample of control in lanes (5&6).0.05 (p < 0.05, two tailed) was considered statistically
significant. The software SPSS (win version 13.0, SPSS
Corporation, Chicago, Il, USA) was used in the analysis.Results
Enzymatic activity of different MMPs in urine of bladder
cancer
Matrix Metalloproteinases (MMPs) including high mo-
lecular weights were analyzed in urine of bladder cancer
patients as well as 100 healthy control subjects using
zymographic analysis technique. High frequency of
tumor cases of different uMMPs (63.6%; 42 out of 66)
showed activity whereas none of the healthy control
cases showed any of the MMPs studied. A representative
image of association was observed between each of
MMPs detected in the urine of bladder cancer patients
as compared with the controls (Figure 1). The highest
percent of activity detected was for MMP9 (62%) among
all investigated markers followed by MMP9/NGAL
(60%), MMP2 (55%), MMP9/dimer (53%), the lowest
percent of activity was observed for ADAMTS (25.6%)
and MMP9/TIMP-1 (12.1%).Correlation between MMP-9 dimer with different uMMPs
In the current study, it was noticed that the highest per-
centage of activity of HMW MMPs detected was in
MMP9 dimer (53%). This prompted us to find its cor-
relation with other different uMMPs detected using
multivariant analysis. Data analysis showed a highly sig-
nificant correlation with the activity of MMP2, MMP9,
and MMP9/NGAL. On the other hand, no correlation
found between MMP9 and MMP9/TIMP-1 or ADAMTS
activities as shown in Table 2.analyzed by substrate gel electrophoresis (zymography). Bands of
niform blue staining. Protein marker used to detect the molecular
Urine samples from bladder cancer patients in lane (1–4) show activity
Table 2 The correlation between activities of uMMP-9
dimer with different uMMPs examined in bladder cancer
patients




(31) (53) (kappa test)
MMP-2
Negative 26 (83.9) 4 (11.4) 30
Positive 5 (16.1) 31 (88.6) 36 0.726 <0.001
MMP-9
Negative 24 (77.4) 1 (2.9) 25
Positive 7 (22.6) 34 (97.1) 41 0.754 <0.001
MMP-9/NGAL
Negative 25 (80.6) 1 (2.9) 26
Positive 6 (19.4) 34 (97.1) 40 0.785 <0.001
MMP-9/TIMP
Negative 29(93.5) 29 (82.9) 58
Positive 2 (6.5) 6 (17.1) 8 0.102 >0.05
ADAMTS-7
Negative 26 (83.9) 23 (65.7) 49 >0.05
Positive 5 (16.1) 12 (34.3) 17 0.176
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pathological parameters
To assess the correlation between different uMMPs de-
tected in the present study with several clinic-patho-
logical parameters, Pearson Correlation was applied. The
variables included were age, gender, tumor size, stage,
grade, presence of bilharziasis, tumor type, lymph nodes,
invasion to prostatic walls as summarized in Table 3. No
significant correlation was found between the activity of
different MMPs examined with the gender except in
MMP9/TIMP-1 complex, which showed the trend of
higher activity in male more than female patients
(p = 0.063). Likewise, a positive correlation was also
found between the activity of ADAMTS marker and the
age at diagnosis. This correlation was higher in young
age compared to elder group (p = 0.068). High expres-
sion of MMP2, MMP9, MMP9/NGAL, and MMP9/
dimer was observed in high grade patients (3/4) as
compared to low grades (1/2) but did not reach the
significant values. Also, a non significant difference was
reported between the activity of different MMPs with
the tumor size except MMP9/TIMP-1, which showed a
significant high expression in patients with large tumor
size (>5 cm) as compared to low size group (p = 0.032).
High expression of different uMMPs investigated with
the presence of muscle invasion to prostate but this cor-
relation was not significant enough. A non-significant
increase in the activity of uMMPs was found towards
bilharzial bladder cancer patients as compared to nonbilharzial once. No association was observed with tumor
type or lymph node involvement. We could not make a
correlation between the activities of MMPs with tumor
staging due to the insufficient biopsy for staging process.
Sensitivity and specificity in MMPs markers
Sensitivity, specificity, accuracy, positive and negative
values for each uMMPs as well as their combination was
tested for detection of bladder cancer. The highest sen-
sitivity was found in uMMP-9 and uMMP-9/NGAL
(62.1% and 60.9%), respectively, followed by MMP-2
(54.5%), and MMP-9 dimer (53%) whereas the lowest
recorded values was observed in ADAMTS (25.8%) and
MMP-9/TIMP(12.1%). The specificity of each marker
examined reached 100% where none of the normal
healthy control cases showed any activity. A combin-
ation of each of the makers examined did not show any
significant increase of the sensitivity as shown in
Table 4.
Discussion
Detection of certain MMPs profile in urine of patients
could provide invaluable information for the tumor biol-
ogy features. The presence of different MMPs including
HMWs (MMP9-dimer, MMP9-TIMP-1, ADAMTS-7)
was reported in the urine of a variety of cancer patients
including bladder [11,12]. Increase of MMP activities
serve to facilitate both tumor cell migration and devel-
opment of new tumor-related blood vessels [10]. The
current study aimed to detect HMW-MMPs gelatinases
in the urine of bladder cancer patients and not only to
predict the disease onset but also to differentiate be-
tween bilharzial and non bilharzial bladder cancer. The
activity of MMPs was detected in urine of 66 bladder
cancer patients as well as 100 normal healthy controls
using zymographic analysis technique. In our study, the
activity of MMP-2 and MMP-9 recorded was 55% and
62%, respectively, and the higher activity of MMP-9 may
be explained as the effect of transcriptional regulation by
inflammatory cytokines such as TNFα and interlukins.
MMP-2 is expressed by many cell types and most likely
is regulated by the level of proenzyme activation [13].
Different independent studies consistently reported ele-
vated MMP-2 activity in urine samples from bladder
cancer as compared to normal healthy subjects, which
confirm our results and raise the hope HMW MMPS
can be used as a diagnostic biomarker for this malig-
nancy [8,14,15]. On the other hand, the secretion of
MMP-9 was enhanced by presence of inflammatory cells
and so the presence of cystitis might lead to false posi-
tive results and decrease specificity [16]. In addition, low
sensitivity of urinary MMP-9 was detected in bladder
cancer, which was approximately 40% in two independ-
ent studies [14,16] including our study (62%), showing a
Table 3 The correlation between the activities of different uMMPs with clinico-pathological parameters
Clinic-pathological
parameters
MMP-2 MMP-9 MMP-9/NGAL MMP-9 dimer MMP-9/TIMP ADAMTS
(%) (%) (%) (%) (%) (%)
Gender
Male 56.3 65.6 62.5 54.2 16.7 25.0
Female 50.0 55.6 55.6 50.0 0.0 27.8
Age (year)
≤ 60 47.8 52.2 56.5 47.8 34.8 21.7
> 60 58.1 67.4 62.8 53.5 20.8 7.0
Tumor size
≤ 5 cm 52.8 58.3 58.3 52.8 16.7* 13.9
> 5 cm 58.3 70.8 66.7 50.0 41.7 12.5
Tumor type
TCC 55.6 62.2 60.0 53.3 13.3 22.2
SCC 52.4 61.9 61.9 52.4 9.5 33.3
Grade
1/2 48.8 58.1 53.3 48.8 16.3 27.9
3/4 65.0 70.0 75.0 65.0 5.0 20.0
Bilharziasis
Present 59.1 72.7 68.2 45.5 18.2 36.4
Absent 52.3 56.8 56.8 56.8 9.1 20.5
Lymph nodes
Present 25.0 75.0 75.0 25.0 50.0 50.0
Absent 52.4 61.9 59.5 54.8 14.5 28.6
Prostatic invasion
Present 60.0 80.0 80.0 60.0 20.0 30.0
Absent 42.9 50.0 50.0 50.0 14.3 21.4
* Statistically significant.
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type of malignancy. The higher activity of both MMP-2
and MMP-9 were detected in high grades and muscle
invasion to prostate gland and this may indicate their
role in the progression of disease. Also, higher levels ofTable 4 Sensitivity, specificity, accuracy, PPV and NPV for diff
Markers Total (%) MMP-2 (%) MMP-9 (%) MMP-9/NGA
Sensitivity 42/66 36/66 41/66 40/66
(63.6) (54.5) (62.1) (60.9)
Specificity 100/100 100/100 100/100 100/100
(100) (100) (100) (100)
Accuracy 142/166 136/166 141/166 140/166
(85.5) (81.9) (84.9) (84.9)
PPV 42/42 36/36 41/41 40/40
(100) (100) (100) (100)
NPV 100/124 100/130 100/125 100/126
(80.6) (76.9) (80) (79.4)
PPV: positive predictive value.
NPV: negative predictive value.gelatinases (2 & 9) in bilharzial bladder cancer patients
compared to their counterpart control might have cli-
nical relevance in the detection of this specific type of
bladder cancer. The non – significant association be-
tween MMPs and other clinical parameters probablyerent uMMPs in bladder cancer patients
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study warrants further investigations to clarify this
finding.
When MMP-9 present in excess amount relative to its
endogenous inhibitor TIMP, it can form dimmers.
MMP-9 dimer has been identified in a variety of MMP-9
producing cells including neutrophils and normal breast
epithelial cells [17,18] and is a component of normal
plasma [19]. Enzymatic activity of the monomeric and
dimeric forms of MMP-9 does not differ; however, the
dimer can be activated by stromelysin with much lower
efficiency (10 fold less) than monomer [19]. The exis-
tence of more stable, slow activating MMP-9 dimer
might serve as a regulatory mechanism during extracel-
lular matrix degradation [19]. In our study, MMP-9 was
the most detectable gelatinases in the urine of bladder
cancer patients which means a relative excess level of
MMP-9 relative to TIMP-1 produced by the primary
tumor and surrounding stroma. This in turn resulted in
elevated levels of both monomeric and diametric forms
of this protease in urine [12].
It was previously demonstrated that the ~125 kDa
MMP activity in the urine of cancer patients is a com-
plex of MMP-9 and NGAL [11], which may represent a
new biomarker for the prediction of cancer disease [20].
Several studies reported an elevation of this enzyme
activity in the urine of variety of cancer including blad-
der cancer [20,21]. The formation of NGAL-MMP-9
complex has the ability to protecting MMP-9 from
autodegradation. MMP-9/NGAL complex was detected
more frequently in the urine of metastatic cancer than
other types of disease. It is believed that invasive cap-
acity of MMP-9 is enhanced when it is bound to NGAL
and that is associated with metastasis [11]. In the
current study, MMP-9/NGAL enzyme activity was de-
tected in about 60% of the urine specimens of the blad-
der cancer patients but not in any of the urine control
healthy cases (p = 0.001). However, no marked difference
was recorded in the ration of NGAL within bilharzial
and non bilharzial bladder cancer patients or even
between the TCC and SCC types. Likewise, MMP-2 and
9 had no significant difference in high grade and muscle
invasion bladder cancer cases which confirm their role
in the tumor progression.
Here, we report that the 190 kDa gelatinase (ADA
MTS-7) was detected in the urine of a little number of
bladder cancer patients (26%). To date, ADAMTS-7
has yet to be associated with human cancers except
with those reported by Roy et al. [12]. ADAMTS-7 is a
family of disintegrin zinc – dependent proteases that
have at least one thrombospondin type I motif [12]. A
non significant correlation was recorded between the
enzymes activities with different clinico- pathological
parameters.MMP-9/TIMP-1 complex was reported to be serum
marker for fibrosis in children with chronic hepatitis B
[22]. However, very little is known about its correlation
with cancer. In this study, we found that urine from
bladder cancer patients indicated the presence of 140 kDa
MMP- 9/TIMP-1 complex but it was unfrequented in
urine of those patients.
Taken together, our study detected many species of
gelatinases in the urine of bladder cancer patients with
primary tumor (both bilharzial and non bilharzial)
including MMP-2, MMP-9, MMP-9 dimer, MMP-9/
NGAL, MMP-9/TIMP-1 and ADAMTS-7. Each MMP
was detected at significantly higher rate in urine from
cancer patients compared to control subjects except in
MMP-9/TIMP-1 and ADAMTS-7. The activity of urin-
ary MMPs is a promising diagnostic tool and can be
used as biomarkers for predicting bladder cancer. The
study also revealed that the detection of urinary HMW
gelatinases was not able to differentiate between bilhar-
zial and non bilharzial bladder cancer subtypes.Conclusions
This study revealed that the detection of urinary MMPs
including HMWs activity might be sensitive biomarkers
for prediction of bladder cancer. It is also demonstrate
that the detection of these urinary HMW gelatinases
could not differentiate between bilharzial and non bil-
harzial bladder cancer subtypes.Competing interests
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